Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making
September 9, 2009
By:
George Koroneos, Online Content & News Editor
Some shareholders think they were shafted in the multi-billion dollar deal between Sepracor and Dainippon Sumitomo Pharma. They're so miffed, in fact, that they've filed a lawsuit stating that the amount offered undervalues the company and its shares.
|
April 22, 2009
Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line.
|
April 22, 2009
By:
George Koroneos, Online Content & News Editor
The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market.
|
March 12, 2009
By:
Walter Armstrong, Senior Editor
The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion.
|
March 5, 2009
By:
George Koroneos, Online Content & News Editor
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.
|
March 4, 2009
By:
George Koroneos, Online Content & News Editor
The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
